Literature DB >> 12546363

Characterization of the levels of expression of retinoic acid receptors, galectin-3, macrophage migration inhibiting factor, and p53 in 51 adamantinomatous craniopharyngiomas.

Florence Lefranc1, Catherine Chevalier, Mathieu Vinchon, Patrick Dhellemmes, Max-Peter Schüring, Herbert Kaltner, Jacques Brotchi, Marie-Magdeleine Ruchoux, Hans-Joachim Gabius, Isabelle Salmon, Robert Kiss.   

Abstract

OBJECT: Craniopharyngiomas are histopathologically defined as benign tumors that can behave very aggressively at the clinical level. They can originate from different types of embryonal epithelial tissue in which correct spatiotemporal regulation has been disrupted at the effector production level. The goal of this study was to determine the efficacy of using selected biological markers to distinguish between recurring and nonrecurring craniopharyngiomas.
METHODS: The authors used computer-assisted microscopy to determine quantitatively the immunohistochemical levels of expression of selected markers, including retinoic acid receptors (RARs), as response elements to retinoic acid in a series of 51 adamantinomatous craniopharyngiomas. These tumors may also originate as the result of physiological defects in the apoptosis-mediated elimination of embryological remnants of epithelial tissue. Galectin-3, p53, and the macrophage migration inhibiting factor (MIF) are known to play crucial roles in these processes. The authors quantitatively determined the levels of expression of these substances in this series of 51 craniopharyngiomas. The data show that all craniopharyngiomas were immunoreactive for RARalpha, whereas their immunoreactivity for RARbeta and RARgamma varied dramatically from one case to another. Craniopharyngiomas with low levels of RARbeta and high levels of RARgamma are more likely to recur than those with higher levels of RARbeta and lower levels of RARgamma. Rapidly recurring craniopharyngiomas also show significantly lower levels of expression of galectin-3 and MIF than nonrecurring or slowly recurring cases. Few tumors exhibited p53 immunopositivity.
CONCLUSIONS: The data indicate that even in the so-called adamantinomatous group of craniopharyngiomas, several subgroups with different clinical behavior patterns can be identified on the basis of differentiation markers relating mainly to the presence or absence of RARbeta and RARgamma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12546363     DOI: 10.3171/jns.2003.98.1.0145

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  6 in total

Review 1.  Histopathological and molecular predictors of growth patterns and recurrence in craniopharyngiomas: a systematic review.

Authors:  Josephine R Coury; Brittany N Davis; Christoforos P Koumas; Giovanna S Manzano; Amir R Dehdashti
Journal:  Neurosurg Rev       Date:  2018-04-17       Impact factor: 3.042

2.  Treatment of Cystic Craniopharyngiomas: An Update.

Authors:  Federico Bianchi; Alberto Benato; Luca Massimi
Journal:  Adv Tech Stand Neurosurg       Date:  2022

3.  All-trans retinoic acid inhibits craniopharyngioma cell growth: study on an explant cell model.

Authors:  Qiang Li; Chao You; Liangxue Zhou; Xiutian Sima; Zhiyong Liu; Hao Liu; Jianguo Xu
Journal:  J Neurooncol       Date:  2013-02-20       Impact factor: 4.130

4.  Craniopharyngioma and hypothalamic obesity in children.

Authors:  Matthieu Vinchon; Jacques Weill; Isabelle Delestret; Patrick Dhellemmes
Journal:  Childs Nerv Syst       Date:  2008-12-05       Impact factor: 1.475

5.  Craniopharyngiomas in children: recurrence, reoperation and outcome.

Authors:  Matthieu Vinchon; Patrick Dhellemmes
Journal:  Childs Nerv Syst       Date:  2007-09-05       Impact factor: 1.475

6.  Treatment strategies in childhood craniopharyngioma.

Authors:  Stéphanie Puget
Journal:  Front Endocrinol (Lausanne)       Date:  2012-06-05       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.